Radical cystectomy (RC) is currently the standard of care for non-metastatic muscle invasive bladder cancer. Few studies compare methods of cutaneous continent urinary diversion (CCUD) following RC.
To test the hypothesis that patients under active surveillance (AS) for Non-muscle Invasive Bladder Cancer (NMIBC) who were negative on longitudinal re-testing by the Xpert® Bladder Cancer Monitor (Xpert BC Monitor) assay may avoid unnecessary cystoscopies and urine cytology (UC).
Reno, Nevada (UroToday.com) — Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery will be reported at the 2022 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (GU ASCO) on February 18, 2022.
− First results from SPOTLIGHT trial being presented at 2022 ASCO Genitourinary Cancers Symposium (ASCO GU) − − Totality of results support Company proceeding with New Drug Application to U.S. Food and Drug Administration – Reno, Nevada (UroToday.com) — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative […]
Findings shared at 2022 ASCO GU Symposium are from the first late-stage clinical study validating any gene-expression test for this patient group Reno, Nevada (UroToday.com) — Veracyte, Inc. announced that new data validating the clinical utility of the company’s Decipher Prostate Genomic Classifier for guiding treatment selection in men with intermediate-risk prostate cancer will be presented Thursday, February […]
ASCO PerspectiveReno, Nevada (UroToday.com) — “Current prostate cancer screening recommendations rely on family history as well as race and ethnicity, factors which often don’t fully capture a person’s risk of developing or dying from prostate cancer. This new study suggests that an extensive genetic risk score could be an effective tool to guide screening decisions by […]
Results confirm prolonged sustained complete response, with 71% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) having a complete remission with a median duration of response of 24.1 months By contrast, historical complete response rates for FDA-approved therapies pembrolizumab and valrubicin are of 41% and 18%, respectively1 & 2 In […]
Combination was well tolerated and allowed patients to maintain their quality of life vs. patients treated with abiraterone alone PROpel Phase III trial results show clinically meaningful benefit in patients irrespective of homologous recombination repair gene mutationsReno, Nevada (UroToday.com) — Positive results from the PROpel Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone […]
– Late-breaking data from Cohort H of EV-103 trial to be presented at the 2022 ASCO Genitourinary Cancers Symposium – – Activity, tolerability of enfortumab vedotin support ongoing investigation in Phase 3 trials – Reno, Nevada (UroToday.com) — Astellas Pharma Inc. and Seagen Inc. announced the initial results from Cohort H of the EV-103 trial investigating […]
To test for differences in cancer specific mortality (CSM) rates between radical nephrectomy (RN) and partial nephrectomy (PN) in pT3a nmRCC patients. Within the Surveillance, Epidemiology, and End Results database (2005-2016), 13,177 pT3a patients treated with either PN or RN were identified.